STAT+: Pharmalittle: Eisai executive to retire; Express Scripts adds three Humira biosimilars to formulary
Express Scripts will add three biosimilar versions of AbbVie's blockbuster arthritis treatment Humira to its list of preferred drugs.
Top of the morning to you, and a fine one it is. Birds are chirping and cool breezes are wafting by the Pharmalot campus, where the official mascots are racing about the grounds. As for us, we are ensconced doing the usual sorts of things — updating our to-do list, brewing cups of stimulation (our choice today is chocolate raspberry) and foraging for items of interest. Speaking of which, we have gathered the latest bushel for your perusal if you scroll down a wee bit. Of course, all of this means that it is time to get cracking. So here we go. We hope you have a smashing day and conquer the world. And as always, please do stay in touch …
Eisai announced that Ivan Cheung, who ran its global Alzheimer’s drug program, will retire at the end of the month and be replaced by the son of Eisai chief executive officer Haruo Naito, STAT writes. The move comes after Cheung led the push for U.S. approval of the breakthrough medicine Leqembi. Keisuke Naito, 34, a senior vice president and chief strategy and planning officer, will become acting global Alzheimer’s officer. Cheung’s resignation comes less than a week after Eisai and Biogen were granted full approval for Leqembi in the U.S. The drug is the first medicine shown to slow progression of the disease, which afflicts some 6 million Americans.
Express Scripts will add three biosimilar versions of AbbVie’s blockbuster arthritis treatment Humira to its list of preferred drugs, Reuters notes. The biosimilars include branded and unbranded versions from Sandoz, the generic unit of Novartis, as well as one from Boehringer Ingelheim. Express Scripts, the pharmacy benefits manager owned by Cigna, said the biosimilars would be included as preferred brands on its formulary. The drugs, launched this month, add to competition for Humira in the U.S. that started in January with the launch of a biosimilar by Amgen that is already on Express Scripts formulary.
What's Your Reaction?
